Brighter's main patent granted in Brazil.

Brighter's main patent for Actiste – the world's first complete IoT unit for diabetes monitoring and treatment – has been granted in Brazil. The country is one of Brighter's most important target markets.

About 9% of Brazil’s adult population – some 13 million people – suffer from diabetes, according to the International Diabetes Association (2017). The financial burden of the disease and its complications is high, and there is a strong need for more effective preventive care and everyday treatment.

"This is a strategically important development for Brighter," says CEO Henrik Nyström. "Brazil is the fourth largest country in the world in terms of the absolute number of people with diabetes. Studies show that the majority do not achieve metabolic control."

"In the long term, this is one of the most important markets we intend to establish and will likely be the first South American country we enter. I have previously lived and worked in Brazil, and seen the development up close."

For further information, please contact:

Henrik Norström, CEO
Phone: +46 733 40 30 45
Email: henrik.norstrom@brighter.se

Rasmus Karlgren, Media & Communications Manager
Phone: +4672 999 38 64
Email: rasmus.karlgren@brighter.se

About Actiste
Actiste is the world's first complete IoT care solution for monitoring and treating insulin-dependent diabetes. The tool brings together all the necessary functions for diabetes care –blood sampling, blood glucose measurement and drug injection – in a single connected device. The solutionis based on patented technology for collecting data on specified biomarkers and injected volumes of drugs. With state-of-the-art eSIM technology, Actiste has global out-of-the-box connectivity, which means that it is completely independent of other devices for sharing health and treatment data. Actiste received CE-mark in September 2019.

The Actiste device is delivered as part of a subscription service. The service includes global connectivity, different levels of data sharing, continuous replenishment of consumables directly to the home, and continuous coaching to optimize and improve treatment. https://actiste.com/

About Brighter AB (publ)
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare’s biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/

The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 00, info@eminova.se, www.eminova.se.

About Us

Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of the most serious healthcare problems: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop™ - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and close associates, healthcare providers, research, pharmaceutical industry and society. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/ The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Brighter’s Certified Adviser is Eminova Fondkommission AB +46 (0)8 – 684 211 00, info@eminova.se, www.eminova.se

Subscribe

Documents & Links